← 產業報告目錄

Chapel Disease Therapeutics Market Size, Share & Trends Analysis Report By Type (Eculizumab, Ravulizumab, Veopoz), By Diagnosis (Gastrointestinal Symptoms, Edema, Hypoalbuminemia, Hypogammaglobulinemia, Malnutrition), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031

出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-06頁數 180報告編號 INSIGHTACE-ce334d6683

授權報價

Single User PDF$4,500 USD
Global Site License PDF$9,500 USD
洽詢購買 申請 Sample

報告摘要

Valued at USD 144.89 Mn as of 2023, the global Chapel Disease Therapeutics Market is set to climb to USD 161.10 Mn by 2031, reflecting a compound annual growth rate of 1.41% over the 2024–2031 period. Chapel Disease Therapeutics encompasses a rare genetic condition affecting the immune system. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges. Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives. Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential. From a regional perspective, mature markets in North America and Europe continue to hold substantial shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector. Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing. Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Chaple Disease Therapeutics Market Snapshot Chapter 4. Global Chaple Disease Therapeutics Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis 5.1. by Type & Market Share, 2019 & 2031 5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type: 5.2.1. Eculizumab 5.2.2. Ravulizumab 5.2.3. Veopoz Chapter 6. Market Segmentation 2: by Diagnosis Estimates & Trend Analysis 6.1. by Diagnosis & Market Share, 2019 & 2031 6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Diagnosis: 6.2.1. Gastrointestinal Symptoms 6.2.2. Edema 6.2.3. Hypoalbuminemia 6.2.4. Hypogammaglobulinemia 6.2.5. Malnutrition Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis 7.1. by Distribution Channel & Market Share, 2019 & 2031 7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel: 7.2.1. Retail Pharmacies 7.2.2. Hospital Pharmacies 7.2.3. Online Pharmacies Chapter 8. Chaple Disease Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis 8.1. North America 8.1.1. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 8.1.2. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031 8.1.3. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031 8.1.4. North America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 8.2. Europe 8.2.1. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 8.2.2. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031 8.2.3. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031 8.2.4. Europe Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 8.3. Asia Pacific 8.3.1. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 8.3.2. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031 8.3.3. Asia-Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031 8.3.4. Asia Pacific Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 8.4. Latin America 8.4.1. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 8.4.2. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031 8.4.3. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031 8.4.4. Latin America Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 8.5. Middle East & Africa 8.5.1. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 8.5.2. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031 8.5.3. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031 8.5.4. Middle East & Africa Chaple Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 Chapter 9. Competitive Landscape 9.1. Major Mergers and Acquisitions/Strategic Alliances 9.2. Company Profiles 9.2.1. Alexion Pharmaceuticals Inc. 9.2.2. Akari Therapeutics, Apellis Pharmaceuticals 9.2.3. Amgen Inc. 9.2.4. CinnaGen Co. 9.2.5. Novartis AG 9.2.6. F. Hoffmann-La Roche Ltd 9.2.7. Regeneron Pharmaceuticals Inc 9.2.8. Alnylam Pharmaceuticals 9.2.9. Inc.

量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們